Molecular basis of collagen triple helix recognition by VWF A-like domain two of collagen VII: Implications for interlaced anchoring fibril formation
Journal of Biological Chemistry · 2026
DOI: 10.1016/j.jbc.2026.113448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Moe Hashimoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, School of Advanced Science and Engineering, Waseda University, Shinjuku, Tokyo, Japan. Hauptthemen laut MEDLINE: Collagen Type VII, von Willebrand Factor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anchoring fibrils formed by collagen VII play a critical role in stabilizing the dermal-epidermal junction. The N-terminal non-collagenous (NC1) domain of collagen VII binds firmly to basement membrane components including collagen IV and has also been reported to interact with mesenchymal fibrillar collagens via its von Willebrand factor A-like domain 2 (A2 domain). To elucidate how collagen VII recognizes fibrillar collagen, we performed yeast two-hybrid screening using a triple-helical random peptide library, which resulted in the identification of a Met-Gly-Φ (Φ; aromatic amino acid residue) motif. Biochemical analysis with synthetic triple-helical peptides revealed a binding preference of Trp > Phe as the Φ residue by the A2 domain despite Trp being absent in native collagens. The crystal structure of the A2 domain in complex with the Nle (Met surrogate)-Gly-Trp-containing peptide revealed a unique mechanism by which two distinct hydrophobic pockets of the A2 domain accommodate the Nle and Trp residues corresponding to the Met-Gly-Φ motif, engaging all three chains of the triple helix. Subsequent molecular dynamics simulations demonstrated that the A2 domain recognizes the corresponding native Met-Gly-Phe motif in a similar manner, but with lower affinity, implying a transient interaction with mesenchymal collagens. The findings obtained in this work suggest models in which transient A2-triple helix interaction promotes the recruitment of collagen I and III fibrils into the arc-shaped structure of anchoring fibrils. This also provides a foundation for linking structural understanding to skin fragility diseases caused by collagen VII dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, School of Advanced Science and Engineering, Waseda University, Shinjuku, Tokyo, Japan.
- Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, The University of Osaka, Suita, Osaka, Japan.
- Graduate School of Drug Discovery Sciences, Osaka Metropolitan University, Sakai, Osaka, Japan. Electronic address: kawaharak@omu.ac.jp.
- Department of Chemistry and Biochemistry, School of Advanced Science and Engineering, Waseda University, Shinjuku, Tokyo, Japan. Electronic address: koi@waseda.jp.
Zitieren
APA
Hashimoto, M., Oki, H., Kawahara, K., Fujii, K. K., & Koide, T. (2026). Molecular basis of collagen triple helix recognition by VWF A-like domain two of collagen VII: Implications for interlaced anchoring fibril formation. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.113448
Vancouver
Hashimoto M, Oki H, Kawahara K, Fujii KK, Koide T. Molecular basis of collagen triple helix recognition by VWF A-like domain two of collagen VII: Implications for interlaced anchoring fibril formation. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.113448
BibTeX
@article{Hashimoto2026,
author = {Hashimoto, Moe and Oki, Hiroya and Kawahara, Kazuki and Fujii, Kazunori K and Koide, Takaki},
title = {Molecular basis of collagen triple helix recognition by VWF A-like domain two of collagen VII: Implications for interlaced anchoring fibril formation},
journal = {Journal of Biological Chemistry},
year = {2026},
doi = {10.1016/j.jbc.2026.113448}
}
EUVIMED